Literature DB >> 16738201

Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis.

Carlo Agostini1, Carmela Gurrieri.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible fibrosing lung disease of unknown etiology and with an unfavorable outcome, leading ultimately to death due to respiratory failure. To date, no treatment strategies have been effective in modifying the natural course of IPF and its fatal outcome. The aberrant parenchymal remodeling is characterized by the expansion of fibroblasts/myofibroblasts, which form characteristic subepithelial foci, and by the abnormal deposition of extracellular matrix in the lung parenchyma. Although the pathophysiology underlying this disease has not yet been fully elucidated, animal models of pulmonary fibrosis have provided contributions in dissecting the molecular basis of this disease, focusing on the role of cytokines and chemokines as important pathogenetic mediators of lung fibrosis. Starting with the data obtained from animal models, this article provides a comment on a number of findings that suggest the possible role of the chemokine/cytokine system in the pathogenesis of IPF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16738201     DOI: 10.1513/pats.200601-010TK

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  68 in total

Review 1.  Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together?

Authors:  Christopher L Mosher; Robert J Mentz
Journal:  Am Heart J       Date:  2020-05-06       Impact factor: 4.749

2.  Negative regulation of lung inflammation and immunopathology by TNF-α during acute influenza infection.

Authors:  Daniela Damjanovic; Maziar Divangahi; Kapilan Kugathasan; Cherrie-Lee Small; Anna Zganiacz; Earl G Brown; Cory M Hogaboam; Jack Gauldie; Zhou Xing
Journal:  Am J Pathol       Date:  2011-10-14       Impact factor: 4.307

Review 3.  Towards systems biology of human pulmonary fibrosis.

Authors:  Sean M Studer; Naftali Kaminski
Journal:  Proc Am Thorac Soc       Date:  2007-01

4.  tPA promotes the proliferation of lung fibroblasts and activates the Wnt/β-catenin signaling pathway in idiopathic pulmonary fibrosis.

Authors:  Ling Chen; Jiwei Hou; Xiao Fu; Xiang Chen; Jiang Wu; Xiaodong Han
Journal:  Cell Cycle       Date:  2019-09-24       Impact factor: 4.534

Review 5.  Paracrine functions of fibrocytes to promote lung fibrosis.

Authors:  Kathryn R Kleaveland; Bethany B Moore; Kevin K Kim
Journal:  Expert Rev Respir Med       Date:  2014-01-22       Impact factor: 3.772

6.  Diallyl disulfide inhibits proliferation and transdifferentiation of lung fibroblasts through induction of cyclooxygenase and synthesis of prostaglandin E₂.

Authors:  Yanhua Wang; Rong Cao; Bo Wei; Xiaoyu Chai; Dan Sun; Y Guan; Xin-min Liu
Journal:  Mol Cell Biochem       Date:  2014-04-23       Impact factor: 3.396

7.  Association of monocyte chemoattractant protein-1 (MCP-1)2518A/G polymorphism with proliferative diabetic retinopathy in northern Chinese type 2 diabetes.

Authors:  Li Dong; Xiao Ying Lv; Bin Jie Wang; Ye Qing Wang; Hua Mu; Zhuo Lei Feng; Ping Liu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-09       Impact factor: 3.117

Review 8.  Cardiac manifestations of idiopathic pulmonary fibrosis.

Authors:  Abhinav Agrawal; Isha Verma; Varun Shah; Abhishek Agarwal; Rutuja R Sikachi
Journal:  Intractable Rare Dis Res       Date:  2016-05

9.  The effect of the pro-inflammatory cytokine tumor necrosis factor-alpha on human joint capsule myofibroblasts.

Authors:  Stefan G Mattyasovszky; Alexander Hofmann; Christoph Brochhausen; Ulrike Ritz; Sebastian Kuhn; Jochen Wollstädter; Hendrik Schulze-Koops; Lars P Müller; Bernhard Watzer; Pol M Rommens
Journal:  Arthritis Res Ther       Date:  2010-01-08       Impact factor: 5.156

10.  Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression.

Authors:  Stylianos Bournazos; Jacob Grinfeld; Karen M Alexander; John T Murchison; William A Wallace; Pauline McFarlane; Nikhil Hirani; A John Simpson; Ian Dransfield; Simon P Hart
Journal:  BMC Pulm Med       Date:  2010-10-07       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.